Verve Therapeutics, Inc.
Industry Group: Commercial Services
Country/Region: United States of America
Verve Therapeutics Inc is a genetic medicines company pioneering a new approach to the care of cardiovascular disease, transforming treatment from chronic management to single-course gene editing medicines. The company's initial two programs target PCSK9 and ANGPTL3, genes that have been extensively validated as targets for lowering blood lipids such as low-density lipoprotein cholesterol, a root cause of cardiovascular disease. The company views its operations as and manages its business in one operating segment operating exclusively in the United States.
ESG Risk Rating
Industry Group (1st = lowest risk)
Commercial Services 329 out of 448
Global Universe 6541 out of 15561
What are the ESG Risk Ratings?
Notice: The information is provided as is, for informational, non-commercial purposes only, does not constitute investment advice and is subject to conditions available in our Legal Disclaimer. Usage of this information is not permitted in any way, unless otherwise agreed in writing. By way of exception, usage of this information is permitted to the rated subject, limited to a single reference to the score on the rated subject’s sustainability webpage or CSR report, mentioning Sustainalytics as a source.
|Company||ESG Risk Rating||Industry Rank|
|Healthcare Services Group, Inc.||
|171 out of 448|
|W.A.G. Payment Solutions Plc||
|249 out of 448|
|Repay Holdings Corp.||
|264 out of 448|
|Verve Therapeutics, Inc.||
|329 out of 448|
|China Design Group Co., Ltd.||
|349 out of 448|
For corporate professionals interested in direct competitor insights
Sustainalytics' Peer Performance Insights gives an in-depth analysis of your company's ESG strengths and weaknesses compared to your competitors and industry performance. These insights can be used to identify areas of ESG improvement to help inform future management decisions that align with your organization's sustainability goals.
Our Approach to Calculating ESG Risk
The ESG Risk Ratings measure a company's exposure to industry-specific material ESG risks and how well a company is managing those risks.
Exposure refers to the extent to which a company is exposed to different material ESG issues. Our exposure score takes into consideration subindustry and company-specific factors such as its business model.
Verve Therapeutics, Inc.'s Exposure is Low
Management refers to how well a company is managing its relevant ESG issues. Our management score assesses the robustness of a company's ESG programs, practices and policies.
Verve Therapeutics, Inc.'s Management of ESG Material Risk is Weak